The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China (as of February 2024).
XTANDI and Strategic products
Projects with Focus Area Approach
Others
Rx+® Program
Reference Materials
Please click IR Library: Overview of R&D Pipeline for more detailed information.
Related Links